Immutep Limited Share Price OTC Markets
Stocks
PRRUF
AU000000IMM6
Biotechnology & Medical Research
OTC Markets Traded|
Delayed
OTC Markets
19:19:26 28/09/2026 BST
|
5-day change | 1st Jan Change | ||
| 0.0306 USD | -19.26% |
|
-.--% | -90.47% |
| 09-17 | Immutep refocuses efti development on head and neck cancer and soft tissue sarcoma | FI |
| 09-15 | Immutep's Drug Candidate Now Has Clearer Potential Development Path, Jefferies Says | MT |
| Market Cap | 45.69M 31.9M 28.31M 26.5M 24.02M 45.36M 3.07B 318M 124M 1.57B 120M 117M 5.04B | P/E 2027 * |
-1.82x | P/E 2028 * | -2.82x |
|---|---|---|---|---|---|
| Enterprise Value | -8.91M -6.22M -5.53M -5.17M -4.69M -8.85M -600M -62.1M -24.15M -306M -23.36M -22.86M -984M | EV / Sales 2027 * |
-2.23x | EV / Sales 2028 * | 3.95x |
| Free-Float |
96.85% | Yield 2027 * |
-
| Yield 2028 * | - |
| Markets | Quality | ||
|---|---|---|---|
Australian S.E.
| IMM | Delayed | |
Tradegate
| YP1B | Real-time | |
|
OTC Markets
| PRRUF | Delayed | |
|
Deutsche Boerse AG
| YP1B | Delayed | |
|
Börse Stuttgart
| YP1B | Delayed | |
|
Boerse Muenchen
| YP1B | Real-time |
| 1 day | -19.26% | ||
| 1 month | -19.26% | ||
| 3 months | -38.80% | ||
| 6 months | -23.50% | ||
| Current year | -90.47% |
| 1 month | 0.03 |  | 0.03 |
| Current year | 0.03 | | 0.25 |
| 1 year | 0.03 | | 0.33 |
| 3 years | 0.03 | | 0.33 |
| 5 years | 0.03 | | 0.51 |
| 10 years | 0.01 | | 0.8 |
| Manager | Title | Age | Since |
|---|---|---|---|
Marc Voigt
CEO | Chief Executive Officer | 53 | 08/07/2014 |
David Fang
DFI | Director of Finance/CFO | - | 28/02/2018 |
Stephan Winckels
CTO | Chief Tech/Sci/R&D Officer | - | 30/06/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Marc Voigt
BRD | Director/Board Member | 53 | 08/07/2014 |
Russell Howard
CHM | Chairman | 76 | 16/11/2017 |
Frédéric Triebel
BRD | Director/Board Member | 71 | 12/09/2022 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -19.26% | -.--% | - | - | 31.84M | |
| +4.16% | +3.42% | +49.37% | +94.17% | 74.31B | |
| +2.76% | -1.60% | +22.80% | +78.53% | 56.95B | |
| +0.24% | -1.34% | +3.41% | +34.31% | 48.3B | |
| -4.05% | -2.48% | +328.08% | +696.33% | 44.51B | |
| -1.02% | -2.10% | +28.44% | +32.57% | 43.8B | |
| +1.21% | +0.01% | +6.03% | +110.10% | 41.12B | |
| -0.11% | +2.30% | +9.19% | +58.68% | 31.07B | |
| +4.51% | +8.43% | +37.27% | +34.97% | 28.97B | |
| -1.43% | -2.38% | -8.50% | -13.48% | 24.53B | |
| Average | -1.31% | -0.20% | +52.90% | +125.13% | 43.73B | |
| Weighted average by Cap. | +1.00% | -0.50% | +56.88% | +133.61% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 4M 2.79M 2.48M 2.32M 2.1M 3.97M 269M 27.86M 10.84M 137M 10.48M 10.26M 442M | 3M 2.09M 1.86M 1.74M 1.58M 2.98M 202M 20.9M 8.13M 103M 7.86M 7.69M 331M |
| Net income | -26.1M -18.22M -16.18M -15.14M -13.72M -25.91M -1.76B -182M -70.71M -896M -68.4M -66.93M -2.88B | -30.47M -21.28M -18.89M -17.67M -16.02M -30.26M -2.05B -212M -82.57M -1.05B -79.86M -78.15M -3.36B |
| Net Debt | -54.6M -38.12M -33.84M -31.67M -28.7M -54.21M -3.67B -380M -148M -1.87B -143M -140M -6.03B | -33.83M -23.62M -20.97M -19.62M -17.79M -33.59M -2.28B -236M -91.67M -1.16B -88.67M -86.76M -3.73B |
| Date | Price | Change | Volume |
|---|
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- IMM Stock
- PRRUF Stock
Select your edition
All financial news and data tailored to specific country editions
